RxDoctor Payments Data

Lindsey Gilchrist, NP

Adult Health · New Hartford, NYNPI 1588095384

Payments from drug & device makers

$3,115in general payments, 2019–2025

Across 158 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$373
  • Endo USA, Inc.$239
  • Astellas Pharma US Inc$170
  • GSK$161
  • Antares Pharma, Inc.$145
  • 180 Medical, Inc.$141
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$3,02697%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,115 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$40,850
Medicare patients
339
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron84$93,710
MyrbetriqMirabegron41$51,108
Methenamine Hippurate55$6,903
Tamsulosin Hcl234$3,771
Potassium Citrate ErPotassium Citrate17$2,630
Finasteride133$1,910
Alfuzosin Hcl ErAlfuzosin Hcl45$988
Oxybutynin Chloride15$693
Oxybutynin Chloride ErOxybutynin Chloride47$578
Cephalexin33$398
Allopurinol26$306
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$221
Doxazosin Mesylate14$191
Ciprofloxacin Hcl30$149
Doxycycline Hyclate13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$64$93,71084 claims
Astellas Pharma US IncMyrbetriq$170$51,10841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →